Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Novel Delivery Systems for Checkpoint Inhibitors.

Lamichhane P, Deshmukh R, Brown JA, Jakubski S, Parajuli P, Nolan T, Raja D, Badawy M, Yoon T, Zmiyiwsky M, Lamichhane N.

Medicines (Basel). 2019 Jul 11;6(3). pii: E74. doi: 10.3390/medicines6030074. Review.

2.

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Totiger TM, Srinivasan S, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA 3rd, Joshi C, Rangappa S, Castellanos J, Vemula PK, Chen X, Kwon D, Kashikar N, VanSaun M, Merchant NB, Nagathihalli NS.

Mol Cancer Ther. 2019 Feb;18(2):301-311. doi: 10.1158/1535-7163.MCT-18-0464. Epub 2018 Nov 7.

PMID:
30404927
3.

Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?

Lamichhane P, Amin NP, Agarwal M, Lamichhane N.

Medicines (Basel). 2018 Oct 23;5(4). pii: E114. doi: 10.3390/medicines5040114. Review.

4.

Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer.

Srinivasan S, Totiger T, Shi C, Castellanos J, Lamichhane P, Dosch AR, Messaggio F, Kashikar N, Honnenahally K, Ban Y, Merchant NB, VanSaun M, Nagathihalli NS.

Cancer Res. 2018 Nov 1;78(21):6146-6158. doi: 10.1158/0008-5472.CAN-18-0579. Epub 2018 Sep 19.

PMID:
30232221
5.

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Lamichhane P, Messaggio F, Shi C, Dai X, Rai P, Chen X, VanSaun MN, Merchant NB.

Cancer Res. 2018 Nov 1;78(21):6235-6246. doi: 10.1158/0008-5472.CAN-18-0634. Epub 2018 Aug 28.

PMID:
30154150
6.

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL.

Cancer Res. 2017 Dec 1;77(23):6667-6678. doi: 10.1158/0008-5472.CAN-17-0740. Epub 2017 Oct 9.

7.

Retraction Note: Targeted immune therapy of ovarian cancer.

Knutson KL, Karyampudi L, Lamichhane P, Preston C.

Cancer Metastasis Rev. 2016 Sep;35(3):489. No abstract available.

8.

PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.

Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL.

Cancer Res. 2016 Jan 15;76(2):239-50. doi: 10.1158/0008-5472.CAN-15-0748. Epub 2015 Nov 13.

9.

Tumor-infiltrating dendritic cells in cancer pathogenesis.

Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL.

J Immunol. 2015 Apr 1;194(7):2985-91. doi: 10.4049/jimmunol.1403134. Review.

10.

Targeted immune therapy of ovarian cancer.

Knutson KL, Karyampudi L, Lamichhane P, Preston C.

Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2. Review. Retraction in: Knutson KL, Karyampudi L, Lamichhane P, Preston C. Cancer Metastasis Rev. 2016 Sep;35(3):489.

11.

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.

Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL.

Cancer Res. 2014 Jun 1;74(11):2974-85. doi: 10.1158/0008-5472.CAN-13-2564. Epub 2014 Apr 11.

Supplemental Content

Loading ...
Support Center